Moderna shares (NASDAQ: MRNA) have done something today that few investors genuinely expected to see in a single session. The MRNA share price is trading at $138.27, up 120% on the day, after Moderna and Merck reported positive Phase 3 results for their individualized mRNA-based melanoma vaccine in combination with Merck’s Keytruda. It is the first time an individualized mRNA cancer vaccine has cleared a Phase 3 trial, and the market is treating the news as a fundamental re-rating of the entire Moderna platform, not merely a pipeline check-box.
The move appears to reflect years of investor debate about whether Moderna could ever be more than a Covid vaccine company, resolved in a single morning. The trial showed improved recurrence-free and distant metastasis-free survival in melanoma patients, validating the mRNA-4157 program in a high-value adjuvant setting where treatment cycles are long and pricing is typically premium. That is a different kind of win than a flu shot approval or a Covid booster contract. It suggests the underlying mRNA technology can generate new medicines in oncology, which is precisely the argument bulls have been making and bears have been discounting for the better part of two years.
The magnitude of the price move is almost certainly amplified by positioning dynamics. Short interest in Moderna had been running at elevated levels heading into today, with the stock widely described as a battleground name carrying large dispersion in analyst price targets. When a binary catalyst of this scale breaks decisively in the bull direction, forced short covering can compound the fundamental re-rating into an outsized single-session move.
The catalyst also arrives at a useful moment for the broader Moderna story. The FDA approved the company’s mRNA seasonal flu vaccine, mFLUSIVA, for adults 50 and older earlier this month, giving Moderna its first approved flu product and expanding its commercial respiratory portfolio. That approval had already shifted the narrative somewhat, but the melanoma Phase 3 data is a categorically larger event because it speaks to the platform’s reach beyond respiratory disease entirely.
The macro backdrop is not hurting matters. The Treasury Department announced today that it would at least double its buyback program for long-dated government bonds, pushing 30-year yields down roughly nine basis points and stabilizing risk appetite after a difficult stretch for equities. The Dow is up around 230 points on the session. Technology stocks are under renewed selling pressure, with semiconductor names broadly lower, which means capital is visibly rotating toward healthcare. Moderna is the most dramatic expression of that rotation, but Merck is also up more than 7% on the session, lending additional credibility to the data and providing a lift to the Dow in the process.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
William Blair moved quickly, upgrading Moderna to Outperform from Market Perform this morning and citing the melanoma interim readout and the expected regulatory filing position as the basis for the call. That upgrade is almost certainly the first of several as analysts who had been calibrating their models on Covid and flu economics now have to incorporate the possibility of a meaningful oncology franchise.
Bull Case:
- First successful Phase 3 individualized mRNA cancer vaccine validates the entire platform.
- Short covering on elevated short interest amplifies and sustains the upside move.
- William Blair upgrade signals a broader analyst re-rating cycle is just beginning.
Bear Case:
- Consensus price target near $51 implies the stock is now priced for perfection.
- Regulatory approval and commercial launch could lag meaningful revenue by years.
- Extreme technical extension above Bollinger upper band raises near-term reversal risk.
The bull case rests on regulatory conversion. If Merck and Moderna file for approval in resected stage IIB to IV melanoma and receive a broad patient label, the addressable market for an individualized mRNA cancer vaccine is large and the pricing power is substantial.
Success in melanoma also opens the door to testing the same platform in other tumor types, which would further expand the long-term opportunity. The bear case centers on the gap between a positive trial and a commercial product. Regulatory decisions, label negotiations, and real-world uptake curves all stand between today’s data and meaningful revenue.
Whilst a more than doubling on the day for Moderna shares is no mean feat, extending the YTD rally to 345%, the stock price remains 64% lower than where it sat five years ago. The rebound could well have room to run should further updates prove supportive.
